This grant from the CDC aims to combat tuberculosis, a leading cause of death globally. With a focus on testing and treating high-risk individuals with latent TB infection (LTBI), the goal is to prevent the development of active TB disease. Targeting populations such as non-U.S.-born individuals, those with HIV or diabetes, the homeless, incarcerated, and substance users, the grant supports efforts to eliminate TB in the United States by identifying and curing TB cases and implementing a strategic testing and treatment approach for LTBI. The grant aims to complement state and local health department efforts in TB control without reducing their responsibilities.
Opportunity ID: 316159
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-PS20-2001 |
| Funding Opportunity Title: | Tuberculosis Elimination and Laboratory Cooperative Agreement |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 61 |
| Assistance Listings: | 93.116 — Project Grants and Cooperative Agreements for Tuberculosis Control Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 05, 2019 |
| Last Updated Date: | Jul 05, 2019 |
| Original Closing Date for Applications: | Sep 05, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Current Closing Date for Applications: | Sep 05, 2019 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Archive Date: | Oct 05, 2019 |
| Estimated Total Program Funding: | $0 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | County governments City or township governments State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Competition is limited to 61 project areas, including 50 state public health agencies or their bona fide agents; the cities of Los Angeles, CA; San Francisco, CA; San Diego, CA; Houston, TX; Chicago, IL; New York, NY; Philadelphia, PA; Baltimore, MD; Washington, D.C.; and the territorial governments of Puerto Rico and U.S. Virgin Islands. Eligible applicants with laboratories can apply for laboratory funding. |
Additional Information
| Agency Name: | Centers for Disease Control – NCHHSTP |
| Description: | TB is an airborne disease and globally, a leading cause of death. One fourth of the world’s population is infected with TB. In 2017, 10.0 million people around the world became sick with TB disease. There were 1.3 million TB-related deaths world-wide, and TB is the leading killer of people who are HIV infected. A total of 9,105 TB cases (a rate of 2.8 cases per 100,000 persons) were reported in the United States in 2017. This is a 1.6% decrease in the number of cases reported in 2016 and the lowest case count on record in the United States. While the United States continues to make slow progress, current strategies will not, alone, lead to TB elimination in this century. Meeting the U.S. TB elimination goal will require an added focus on testing and treating high-risk persons with latent TB infection (LTBI) to prevent them from developing active TB disease. CDC estimates that up to 13.0 million people in the United States have LTBI and over 80% of U.S. TB cases result from longstanding, untreated LTBI. This NOFO supports the continued focus on identifying and curing persons with TB disease, but also includes the addition of a targeted testing and treatment strategy for LTBI. TB disproportionately affects certain populations, including those who are non-U.S.-born, with HIV infection or diabetes, experiencing homelessness, who are incarcerated, and who use illicit substances. The TB incidence rate among non-U.S.-born persons in 2017 was approximately 15 times greater compared to U.S.-born persons, and the percentage of TB cases occurring in non-U.S.-born persons continues to increase, reaching 70.1% in 2017. Achieving TB elimination in the United States will require focusing on persons in these high-risk groups – an approach that is reinforced by this NOFO. CDC is continuing a 30-year strategy of funding TB programs through cooperative agreements (CoAgs). The primary responsibility for developing and implementing TB P&C and laboratory activities rests with state and local health departments, and this funding is intended to complement those efforts. The intent of this funding is not to supplant or reduce state and local investment in TB control activities and responsibilities (e.g., provision of medications, in-patient care, and health department facilities). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Glenroy Christie
GPC5@cdc.gov Email:GPC5@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 316159 Full Announcement-FULL_ANNOUNCEMENT -> CDC-RFA-PS20-2001.pdf
Packages
| Agency Contact Information: | Glenroy Christie GPC5@cdc.gov Email: GPC5@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.116 | CDC-RFA-PS20-2001 | Tuberculosis Elimination and Laboratory Cooperative Agreement | PKG00252661 | Jul 05, 2019 | Sep 05, 2019 | View |
Package 1
Mandatory forms
316159 SF424_2_1-2.1.pdf
316159 SFLLL_1_2-1.2.pdf
316159 SF424A-1.0.pdf
316159 BudgetNarrativeAttachments_1_2-1.2.pdf
316159 ProjectNarrativeAttachments_1_2-1.2.pdf
316159 HHS_CheckList_2_1-2.1.pdf
Optional forms
316159 OtherNarrativeAttachments_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
